UK NICE issues second draft ‘no’ on Ninlaro to treat myeloma patients

The UK National Institute for Health and Care Excellence (NICE) has issued a second draft ‘no’ on Takeda’s Ninlaro (ixazomib) for the treatment of patients with relapsed or refractory myeloma.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news